New hope for Hard-to-Treat colorectal cancer: drug combo enters Mid-Stage trial
NCT ID NCT06589830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether a new drug called TL938, taken as a pill, combined with the targeted therapy trastuzumab (given by IV), can shrink tumors in people with HER2-positive colorectal cancer that has spread or come back. The study will enroll 80 adults who have already tried several standard treatments. Researchers aim to find the best dose and measure how many patients respond to the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TL938 capsules and trastuzumab (injection)
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-positive colorectal cancer that has spread and not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to shrink tumors in many participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••